LRRK2 and Parkinson disease: Subgroup analysis of LRRK2 G2019S [21, 22, 27, 29, 31–34] and LRRK2 G2385R variants [25, 26, 28, 36] indicated that PD patients carrying LRRK2 G2019S had 51% lower odds of the risk of RBD compared to those without LRRK2 G2019S (OR, 0.49; 95% CI, 0.39–0.61; I2 = 0.0%) (Fig. 5a), whereas LRRK2 G2385R had no effect on the risk of RBD (OR, 1.53; 95% CI, 0.75–3.13; I2 = 75.5%) (Fig. 5b).